Functional clinical outcomes in multiple sclerosis: Current status and future prospects

Karabudak, Rana; Dahdaleh, Maurice; Aljumah, Mohammed; Alroughani, Raed; Alsharoqi, I.; AlTahan, Abdulrahman; Bohlega, Saeed; Daif, Abdulkader; Deleu, Dirk; Amous, Amer; Inshasi, Jihad; Rieckmann, Peter; Sahraian, Mohammad Ali; Yamout, Bassem

doi:10.1016/j.msard.2015.03.004

Cited by 29 publications

(18 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fingolimod showed the best effect on PASAT and SRT scores, whereas IFN β-1b showed the best effect on SDMT scores. In this regard, it is worth noting that PASAT is a difficult and demanding test of the battery, relatively more difficult than the SDMT, and is sensitive even to early cognitive changes in patients where room for improvement is still limited [ 35 , 36 ]. A longitudinal correlational research study suggested that PASAT is particularly sensitive to inflammatory activity measured by Gd+ enhancement in otherwise physically stable patients with MS [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Comı¹,

Patti²,

Rocca

et al. 2017

J Neurol

View full text Add to dashboard Cite

Cognitive impairment (CI) affects 40–65% of multiple sclerosis (MS) patients. This study attempted evaluating the effects of fingolimod and interferon beta-1b (IFN β-1b) on CI progression, magnetic resonance imaging (MRI) and clinical outcomes in relapsing–remitting MS (RRMS) patients over 18 months. The GOLDEN study was a pilot study including RRMS patients with CI randomised (2:1) to fingolimod (0.5 mg daily)/IFN β-1b (250 µg every other day). CI was assessed via Rao’s Brief Repeatable Battery and Delis–Kaplan Executive Function System test. MRI parameters, Expanded Disability Status Scale scores and relapses were measured. Overall, 157 patients were randomised, of whom 30 discontinued the study (fingolimod, 8.49%; IFN β-1b, 41.18%; p ≤ 0.0001). Patients randomised to fingolimod had more severe clinical and MRI disease characteristics at baseline compared with IFN β-1b. At Month (M) 18, both treatment groups showed improvements in all cognitive parameters. At M18, relapse rate, total number and volume of T2/T1 gadolinium-enhancing lesions were higher with IFN β-1b, as well as the percentage brain volume change during the study. Safety and tolerability of both treatments were similar to previous studies. Both treatments showed improvements in cognitive parameters. Fingolimod demonstrated significantly better effects on MRI parameters and relapse rate. Imbalance in baseline characteristics and the drop-out pattern may have favoured IFN β-1b. A longer duration trial may be needed to observe the complete expression of differential effects on CI scales reflecting the between-groups differences on MRI. Although limited in size, the GOLDEN study confirms the favourable benefit–risk profile of fingolimod reported in previous studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Comı¹,

Patti²,

Rocca

et al. 2017

J Neurol

View full text Add to dashboard Cite

show abstract

“…This review considered the following eight key outcomes in trials of cannabinoids for symptom relief in multiple sclerosis [19]:…”

Section: Types Of Outcomesmentioning

confidence: 99%

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

Nielsen

Germanos

Weier

et al. 2018

Curr Neurol Neurosci Rep

132

View full text Add to dashboard Cite

We identified 11 eligible systematic reviews providing data from 32 studies, including 10 moderate to high quality RCTs. Five reviews concluded that there was sufficient evidence that cannabinoids may be effective for symptoms of pain and/or spasticity in MS. Few reviews reported conclusions for other symptoms. Recent high quality reviews find cannabinoids may have modest effects in MS for pain or spasticity. Future research should include studies with non-cannabinoid comparators; this is an important gap in the evidence.

show abstract

“…Meдико-соціальні прояви захворювання накладають значний відбиток на якість життя пацієнтів, призводячи до значних економічних витрат [5,8]. Численні дослідження [3,9,11] показали, що важкість інвалідизації хворих залежить не лише від вогнищевого демієлінізуючого ураження головного мозку, але й від вираженості нейродегенера-тивних змін. У зв'язку з цим набуває особливого значення визначення ступеня обмеження життєдіяльності осіб, хворих на РС, а також лікування, реабілітація та психологічна корекція порушень.…”

Section: вступunclassified

Indicators of Disability Due to Multiple Sclerosis in Vinnytsia Region

Bezsmertnyi¹,

Bezsmertna²,

Bichak³

et al. 2017

Clin. and experim. pathol.

View full text Add to dashboard Cite

Functional clinical outcomes in multiple sclerosis: Current status and future prospects

Cited by 29 publications

References 83 publications

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

Indicators of Disability Due to Multiple Sclerosis in Vinnytsia Region

Contact Info

Product

Resources

About